Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(50%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_2
1
25%
Ph not_applicable
2
50%
Ph early_phase_1
1
25%

Phase Distribution

1

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
N/ANon-phased studies
2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(2)

Detailed Status

Completed2
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (25.0%)
Phase 21 (25.0%)
N/A2 (50.0%)

Trials by Status

completed250%
recruiting250%

Recent Activity

2 active trials
Showing 4 of 4
recruitingnot_applicable

Defining Neurobiological Links Between Substance Use and Mental Illness

NCT05538910
recruitingearly_phase_1

Evaluation of the Electronic Cigarette Withdrawal Syndrome

NCT06066996
completednot_applicable

Effects of Smoking Environments on Craving and Smoking (CameraCue2.0)

NCT02551692
completedphase_2

Nicotine Patch Trial in Syrian Primary Care Settings

NCT01085032

Clinical Trials (4)

Showing 4 of 4 trials
NCT05538910Not Applicable

Defining Neurobiological Links Between Substance Use and Mental Illness

Recruiting
NCT06066996Early Phase 1

Evaluation of the Electronic Cigarette Withdrawal Syndrome

Recruiting
NCT02551692Not Applicable

Effects of Smoking Environments on Craving and Smoking (CameraCue2.0)

Completed
NCT01085032Phase 2

Nicotine Patch Trial in Syrian Primary Care Settings

Completed

All 4 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
4